Bend Research and Catalent Partner to Provide Integrated Solutions for Oral Controlled-Release Technologies
June 21, 2012
Bend, OR and Somerset, NJ – Bend Research Inc. and Catalent Pharma Solutions, Inc. have entered into an agreement to provide integrated solutions for pharmaceutical companies seeking to develop and manufacture specialized multiparticulate oral controlled-release products.
Under the agreement, Bend Research and Catalent will provide an integrated approach to bring complex controlled-release products to market faster and more efficiently with optimal therapeutic and release profiles.
The companies’ combined expertise in formulation development and Catalent's breadth of services in analytical/CMC, solid-state optimization, clinical and commercial supply will provide pharmaceutical companies with optimal dosage forms and a more efficient path to market. Catalent and Bend Research are developing joint operations and technology-transfer protocols to make the customer experience seamless and efficient while leveraging the strengths of both companies to develop better treatments for patients globally.
"Our integrated approach is geared toward complex, multiparticulate controlled-release products, which traditionally have presented a high scale-up risk when they are transferred to commercial manufacturing sites," said Rod Ray, CEO of Bend Research. "This partnership with Catalent will provide an efficient pathway for these medicines from early development through commercialization. We believe that Catalent's breadth of services and demonstrated success in bringing controlled-release products to market, as well as supplying them globally, makes them an ideal complement to our development strengths."
Ian Muir, president of Catalent’s Modified Release Technologies business, indicated that "Catalent and Bend are aligning their scientific expertise and processes to ensure that developments are undertaken from Day One based on Quality by Design principles. Bend’s added laboratory scale modeling expertise will enhance and increase the efficiencies that Catalent will provide to customers to bring difficult to formulate and manufacture controlled-release compounds to market faster, with optimal product profiles. This should enable optimal and seamless scale-up within Catalent’s Controlled Release network, and particularly at our Winchester, Ky., facility, which is widely regarded as the leading commercial facility for multiparticulate products."
About Bend Research Inc.
For more than 35 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding.
Bend Research provides several capabiltiies, including formulation and dosage-form support, assists in process development and optimization, manufactures clinical-trial quantities of drug candidates in its cGMP facilities, and advances promising drug candidates from conception through commercialization. Bend Research is a leader in novel formulations, including SDDs and hot-melt extrusions, and controlled-release, inhalation and biotherapeutic technologies.
Bend Research has more than 275 employees based in four state-of-the-art facilities in Bend, Ore., USA.
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.